X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (230230) 230230
Newspaper Article (9860) 9860
Newsletter (5636) 5636
Magazine Article (709) 709
Book Chapter (610) 610
Government Document (257) 257
Trade Publication Article (194) 194
Book / eBook (189) 189
Dissertation (109) 109
Conference Proceeding (90) 90
Web Resource (68) 68
Publication (53) 53
Transcript (47) 47
Book Review (39) 39
Reference (19) 19
Report (14) 14
Streaming Video (4) 4
Paper (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (128174) 128174
male (107922) 107922
animals (100238) 100238
female (77763) 77763
rats (49787) 49787
middle aged (47147) 47147
kidney - drug effects (44056) 44056
adult (41129) 41129
kidneys (32461) 32461
urology & nephrology (31905) 31905
aged (31450) 31450
kidney diseases (27085) 27085
kidney - metabolism (26226) 26226
kidney (23090) 23090
mice (22130) 22130
transplantation (21889) 21889
pharmacology & pharmacy (19961) 19961
risk factors (19857) 19857
kidney transplantation (18825) 18825
research (17074) 17074
time factors (16992) 16992
kidney - pathology (16279) 16279
hypertension (15543) 15543
treatment outcome (15383) 15383
surgery (14812) 14812
dose-response relationship, drug (13800) 13800
analysis (13791) 13791
nephrology (13515) 13515
care and treatment (12936) 12936
mortality (12845) 12845
diabetes (12575) 12575
health aspects (12444) 12444
physiology (11970) 11970
adolescent (11430) 11430
blood pressure - drug effects (11402) 11402
rats, sprague-dawley (11397) 11397
oxidative stress (11302) 11302
expression (11298) 11298
immunology (11123) 11123
chronic kidney failure (10763) 10763
retrospective studies (10599) 10599
patients (10530) 10530
oncology (10366) 10366
glomerular filtration rate (10119) 10119
dogs (10035) 10035
cell line (9998) 9998
rats, wistar (9996) 9996
disease (9962) 9962
biochemistry & molecular biology (9940) 9940
liver - drug effects (9814) 9814
cancer (9697) 9697
medicine (9630) 9630
medical research (9525) 9525
creatinine - blood (9456) 9456
toxicology (9424) 9424
kidney - physiopathology (9327) 9327
liver (9312) 9312
research article (9267) 9267
blood pressure (9244) 9244
medicine & public health (9149) 9149
proteins (9049) 9049
hemodialysis (8940) 8940
child (8476) 8476
inflammation (8436) 8436
kidney failure, chronic - therapy (8395) 8395
cells, cultured (8333) 8333
chronic kidney-disease (8310) 8310
rodents (8215) 8215
medicine, general & internal (8212) 8212
therapy (8057) 8057
apoptosis (8025) 8025
chronic kidney disease (8015) 8015
kidney diseases - chemically induced (7968) 7968
disease models, animal (7937) 7937
aged, 80 and over (7727) 7727
kidney function tests (7717) 7717
studies (7619) 7619
metabolism (7571) 7571
physiological aspects (7564) 7564
cell biology (7480) 7480
kidney - physiology (7475) 7475
risk (7463) 7463
prospective studies (7456) 7456
immunosuppressive agents - therapeutic use (7442) 7442
liver - metabolism (7384) 7384
renal dialysis (7356) 7356
follow-up studies (7340) 7340
drug therapy (7136) 7136
medicine, research & experimental (7082) 7082
toxicity (7047) 7047
medicine, experimental (6910) 6910
kidney failure, chronic - complications (6883) 6883
prognosis (6862) 6862
rats, inbred strains (6844) 6844
rabbits (6712) 6712
peripheral vascular disease (6670) 6670
kinetics (6642) 6642
drugs (6614) 6614
endocrinology & metabolism (6614) 6614
cells (6604) 6604
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (75) 75
Online Resources - Online (13) 13
St. Michael's Hospital - Stacks (5) 5
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
Humber River Regional Hospital - Church Stacks (2) 2
Lakeridge Health Sciences - Oshawa (2) 2
Scarborough Hospital - Birchmount (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Reference (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Credit Valley Hospital - Reserve desk (1) 1
Credit Valley Hospital - Stacks (1) 1
Dentistry (Harry R Abbott) - Course Reserves (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Gerstein Science - May be requested in 6-10 wks (1) 1
Gerstein Science - Searching (1) 1
Humber River Regional Hospital - Church Reference (1) 1
Media Commons - Microtexts (1) 1
Scarborough Hospital - General (1) 1
St. Michael's Hospital - Online (1) 1
Stacks (1) 1
Sunnybrook Health Sciences Centre - Holland Reference (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (1) 1
Toronto East General Hospital - Stacks (1) 1
Trillium Health Centre - Online (1) 1
Trillium Health Centre - Reserve desk (1) 1
Trillium Health Centre - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (235975) 235975
German (3218) 3218
Japanese (3203) 3203
Russian (2370) 2370
French (2282) 2282
Chinese (1408) 1408
Spanish (1045) 1045
Italian (1011) 1011
Polish (659) 659
Portuguese (476) 476
Czech (162) 162
Dutch (157) 157
Hungarian (119) 119
Ukrainian (119) 119
Danish (111) 111
Bulgarian (100) 100
Swedish (88) 88
Norwegian (85) 85
Croatian (64) 64
Romanian (57) 57
Turkish (56) 56
Slovak (39) 39
Korean (37) 37
Serbian (37) 37
Finnish (34) 34
Hebrew (23) 23
Arabic (19) 19
Persian (13) 13
Lithuanian (12) 12
Slovenian (6) 6
Indonesian (4) 4
Afrikaans (2) 2
Armenian (1) 1
Bosnian (1) 1
Greek (1) 1
Hindi (1) 1
Icelandic (1) 1
Latvian (1) 1
Urdu (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of translational medicine, ISSN 1479-5876, 2019, Volume 17, Issue 1, pp. 127 - 14
...) especially in those with HF at baseline. These might indicate a potent direct cardioprotective effect, which is currently incompletely understood... 
Sodium-glucose cotransporter-2 inhibitor | Cardioprotection | Canagliflozin | Myocardial ischemia-reperfusion injury | MEDICINE, RESEARCH & EXPERIMENTAL | CARDIOVASCULAR OUTCOMES | SGLT2 INHIBITORS | PHOSPHORYLATION | KINASE | CARDIOMYOCYTES | HEART | PRESSURE | AMPK | ARTERY | Apoptosis - drug effects | Canagliflozin - pharmacology | Myocardial Reperfusion Injury - complications | Systole - drug effects | Male | Aldehydes - metabolism | Liver - physiopathology | Cardiotonic Agents - therapeutic use | Liver - drug effects | Canagliflozin - therapeutic use | Diastole - drug effects | Aorta - physiopathology | Myocardial Reperfusion Injury - drug therapy | Phosphorylation - drug effects | Kidney - physiopathology | Biomarkers - metabolism | Endothelium - pathology | Glycosuria - physiopathology | Kidney - drug effects | Aorta - drug effects | Ventricular Function, Left - drug effects | Cardiotonic Agents - pharmacology | Rats, Sprague-Dawley | Glycosuria - complications | Myocardial Reperfusion Injury - physiopathology | Endothelium - physiopathology | Aorta - pathology | Endothelium - drug effects | Animals | Signal Transduction - drug effects | Oxidative Stress - drug effects | Vasodilation - drug effects | Blood Glucose - metabolism | Myocardial Reperfusion Injury - prevention & control | Nitrosative Stress - drug effects | Heart failure | Diabetics | Rats as laboratory animals | Analysis | Clinical trials | Research | Drug therapy | Health aspects | Occlusion | Myocardial infarction | Heart | Oxidative stress | Phosphorylation | Drug delivery systems | Intravenous administration | Heart attacks | Bax protein | 4-Hydroxynonenal | Bcl-2 protein | AKT protein | Myocardial ischemia | mRNA | Size determination | Kinases | Vasodilation | Proteins | Reperfusion | Ischemia | Rodents | Calcium-binding protein | Aorta | Heart diseases | Injury analysis | Medical research | Adenosine monophosphate | AMP | Diabetes mellitus | Coronary artery | Gene expression | Nitric-oxide synthase | Endothelium | Sodium | Protein kinase | Adenosine kinase | Nitric oxide | Ventricle | Diabetes | Laboratory animals | Apoptosis | Myocardial ischemia–reperfusion injury | Sodium–glucose cotransporter-2 inhibitor
Journal Article
PloS one, ISSN 1932-6203, 2013, Volume 8, Issue 1, p. e53745
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 0027-8874, 2012, Volume 104, Issue 2, pp. 93 - 113
With the advent of targeted agents for the treatment of renal cell carcinoma (RCC), overall survival has improved, and patients are being treated continuously... 
TYROSINE KINASE INHIBITORS | CONTROLLED-TRIAL | INTERFERON-ALPHA | SUNITINIB TREATMENT | CANCER-PATIENTS | VENOUS THROMBOEMBOLISM | ONCOLOGY | HEART-FAILURE | DOUBLE-BLIND | EXPANDED ACCESS PROGRAM | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Hypothyroidism - chemically induced | Pneumonia - therapy | Anorexia - therapy | Humans | Drug Eruptions - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Kidney Neoplasms - metabolism | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Weight Loss - drug effects | Benzenesulfonates - adverse effects | Bevacizumab | TOR Serine-Threonine Kinases - antagonists & inhibitors | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Pyrroles - adverse effects | Antineoplastic Agents - pharmacology | Carcinoma, Renal Cell - drug therapy | Everolimus | Hypothyroidism - therapy | Wound Healing - drug effects | Molecular Targeted Therapy - methods | Sirolimus - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Sirolimus - analogs & derivatives | Europe | Gastrointestinal Tract - drug effects | Cardiovascular System - drug effects | Evidence-Based Medicine | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Anorexia - chemically induced | Kidney Neoplasms - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Drugs | Complications and side effects | Care and treatment | Adverse and side effects | Carcinoma, Renal cell | Research | Drug therapy | Antineoplastic agents
Journal Article
RNA (Cambridge), ISSN 1355-8382, 2012, Volume 18, Issue 7, pp. 1373 - 1384
The recruitment of ribosomes to eukaryotic cellular mRNAs requires the activity of two prototypic RNA helicases, eukaryotic initiation factor (eIF) 4AI and... 
Translation | eIF4AI | eIF4AII | DEAD-box RNA helicase | Hippuristanol | Translational control | RNA helicase | MAMMALIAN TRANSLATION | FACTOR EIF-4A | BIOCHEMISTRY & MOLECULAR BIOLOGY | BINDING-PROTEIN | CROSS-LINKING | translational control | 5' END | EUKARYOTIC TRANSLATION INITIATION | MESSENGER-RNA | translation | hippuristanol | DEGRADATION | INHIBITS TRANSLATION | RNA HELICASE EIF4A | Transcription, Genetic - drug effects | Testis - metabolism | Humans | Fetus - metabolism | Male | Muscle, Skeletal - metabolism | Spleen - drug effects | Prostate - metabolism | Testis - drug effects | Brain - metabolism | Kidney - metabolism | Protein Isoforms - metabolism | Liver - drug effects | Muscle, Skeletal - drug effects | Myocardium - metabolism | Prostate - drug effects | Adult | Female | Ovary - drug effects | Lung - metabolism | Thymus Gland - metabolism | Ovary - metabolism | Sterols - pharmacology | Cell Line | Kidney - drug effects | Liver - metabolism | Pancreas - drug effects | Pancreas - metabolism | Thymus Gland - drug effects | Eukaryotic Initiation Factor-4A - antagonists & inhibitors | Brain - drug effects | Fetus - drug effects | Placenta - drug effects | Placenta - metabolism | Pregnancy | Transcription, Genetic - physiology | Spleen - metabolism | Lung - drug effects | Eukaryotic Initiation Factor-4A - metabolism
Journal Article
Circulation research, ISSN 0009-7330, 02/2007, Volume 100, Issue 3, pp. 342 - 353
A large body of evidence has accrued indicating that voltage-gated Ca channel subtypes, including L-, T-, N-, and P/Q-type, are present within renal vascular... 
Renal microcirculation | Mibefradil | channels | Afferent arteriole | channel blockers | Efferent arteriole | Renal disease | Voltage-dependent Ca | Efonidipine | Ca | Ca2+ channel blockers | N-TYPE | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFERENT ARTERIOLES | efonidipine | SPONTANEOUSLY HYPERTENSIVE-RATS | RHO-KINASE INHIBITOR | renal microcirculation | ANGIOTENSIN-II | T-TYPE | renal disease | mibefradil | DEPENDENT CALCIUM-CHANNELS | CARDIAC L-TYPE | RENAL MICROVASCULAR CONSTRICTION | efferent arteriole | voltage-dependent Ca2+ channels | PERIPHERAL VASCULAR DISEASE | afferent arteriole | HEMATOLOGY | IN-VIVO VISUALIZATION | Arterioles - physiology | Kidney - physiology | Protein Subunits | Antihypertensive Agents - pharmacology | Kidney - blood supply | Humans | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Antihypertensive Agents - classification | Calcium Channels - physiology | Calcium Channels, T-Type - chemistry | Neurotransmitter Agents - secretion | Calcium Channels - drug effects | Calcium Channels, N-Type - drug effects | Cardiovascular Diseases - physiopathology | Kidney - drug effects | Calcium Channels - classification | Rats | Calcium Channels, L-Type - physiology | Antihypertensive Agents - therapeutic use | Arterioles - drug effects | Disease Progression | Antihypertensive Agents - adverse effects | Mice, Knockout | Calcium Signaling - drug effects | Diabetes Mellitus - physiopathology | Models, Biological | Calcium Channels - chemistry | Calcium Channels, T-Type - drug effects | Mice | Vasodilation - drug effects | Hydronephrosis - physiopathology | Calcium Channel Blockers - adverse effects | Calcium Signaling - physiology | Cardiovascular Diseases - drug therapy | Renal Circulation - physiology | Microcirculation - drug effects | Microcirculation - physiology | Renal Circulation - drug effects | Blood Pressure - drug effects | Calcium Channels, L-Type - chemistry | Kidney Diseases - metabolism | Calcium Channels, T-Type - physiology | Renin - secretion | Aldosterone - physiology | Kidney Diseases - drug therapy | Renin-Angiotensin System - physiology | Calcium Channel Blockers - pharmacology | Hypertension - physiopathology | Animals | Calcium Channels, L-Type - drug effects | Calcium Channels, N-Type - physiology | Calcium Channels, N-Type - chemistry
Journal Article
PloS one, ISSN 1932-6203, 2012, Volume 7, Issue 3, p. e33258
Acute tubular necrosis (ATN) caused by ischemia/reperfusion (I/R) during renal transplantation delays allograft function. Identification of factors that... 
ACUTE KIDNEY INJURY | ISCHEMIA/REPERFUSION INJURY | ACTIVATION | ERYTHROPOIETIN | EPITHELIAL-CELLS | FACTOR-1-ALPHA | DISEASE | BIOLOGY | GENE-EXPRESSION | NITRIC-OXIDE | LOW-OXYGEN TENSION | Immunohistochemistry | Oxygen - pharmacology | Transcription, Genetic - drug effects | Kidney Tubular Necrosis, Acute - complications | TOR Serine-Threonine Kinases - metabolism | Humans | Middle Aged | Male | Transplantation, Homologous | Young Adult | Hypoxia-Inducible Factor 1, alpha Subunit - metabolism | Adult | Female | Reperfusion Injury - complications | Proto-Oncogene Proteins c-akt - metabolism | Reperfusion Injury - genetics | Reperfusion Injury - metabolism | Cell Survival - drug effects | Cell Hypoxia - drug effects | Kidney Tubules, Proximal - pathology | Reperfusion Injury - pathology | Rats | Epithelial Cells - pathology | Kidney Transplantation | Gene Expression Regulation - drug effects | Animals | Signal Transduction - drug effects | Epithelial Cells - enzymology | Kidney Tubules, Proximal - metabolism | Aged | Kidney Tubular Necrosis, Acute - pathology | Kidney Tubules, Proximal - drug effects | Kidneys | Ischemia | Cell death | Analysis | Genes | Transplantation | Gene expression | Hypoxia-inducible factor 1 | Nephrology | Oxygen | Cell survival | Renal function | Transplants & implants | Interference | Tubules | Proximal tubules | Epithelium | Immunology | Reperfusion | Metabolites | Rodents | Hypoxia | Kidney diseases | Oxygen tension | Vascular endothelial growth factor | Cancer | Kidney transplantation
Journal Article
Free Radical Research, ISSN 1071-5762, 05/2011, Volume 45, Issue 5, pp. 575 - 584
Abstract The beneficial effects of telmisartan on Angiotensin (Ang)-II mediated oxidative stress and renal fibrosis in streptozotocin (STZ... 
Renin-angiotensin-aldosterone system | fibrosis | telmisartan | diabetic nephropathy | oxidative stress | Kidney - pathology | Receptors, G-Protein-Coupled - metabolism | Intracellular Signaling Peptides and Proteins - drug effects | Transforming Growth Factor beta1 - metabolism | Collagen Type III - metabolism | NADPH Oxidases - metabolism | Diabetic Nephropathies - drug therapy | Receptor, Angiotensin, Type 2 - drug effects | Intracellular Signaling Peptides and Proteins - metabolism | Peptidyl-Dipeptidase A - drug effects | Angiotensin II Type 1 Receptor Blockers - pharmacology | Kidney - metabolism | NADPH Oxidases - drug effects | Diabetes Mellitus, Experimental | Peptidyl-Dipeptidase A - metabolism | Superoxides - metabolism | Transforming Growth Factor beta1 - drug effects | Receptor, Angiotensin, Type 1 - drug effects | Receptors, G-Protein-Coupled - drug effects | Protein-Serine-Threonine Kinases - metabolism | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - drug effects | Kidney - drug effects | Angiotensin II - metabolism | Antioxidants - pharmacology | Collagen Type III - drug effects | Diabetic Nephropathies - complications | Up-Regulation - drug effects | Hypertrophy - complications | Animals | Receptor, Angiotensin, Type 2 - metabolism | Receptor, Angiotensin, Type 1 - metabolism | Fibrosis | PPAR gamma - agonists | Protein-Serine-Threonine Kinases - drug effects | Benzoates - pharmacology | Benzimidazoles - pharmacology | Mice | Oxidative Stress - drug effects | Hypertrophy - drug therapy
Journal Article
Cancer treatment reviews, ISSN 0305-7372, 2016, Volume 44, pp. 51 - 60
Highlights • Role of immune checkpoint inhibition in the management of key malignancies. • Description of rates of immune-related adverse events and timing of... 
Hematology, Oncology and Palliative Medicine | Pembrolizumab | Immune-related adverse events | Renal cancer | Ipilimumab | Nivolumab | Lung cancer | Melanoma | Immune-checkpoint inhibitors | OPEN-LABEL | SINGLE-ARM | ANTI-CTLA-4 ANTIBODY | METASTATIC MELANOMA | ONCOLOGY | ADVANCED MELANOMA | LONG-TERM SAFETY | MALIGNANT MESOTHELIOMA | ENTERIC NEUROPATHY | ADVERSE EVENTS | IPILIMUMAB RETREATMENT | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Adrenal Cortex Hormones - therapeutic use | Diarrhea - chemically induced | Infliximab - therapeutic use | Drug Eruptions - drug therapy | Antineoplastic Agents - adverse effects | Colitis - chemically induced | Antilymphocyte Serum - therapeutic use | Colitis - drug therapy | Carcinoma, Renal Cell - drug therapy | Chemical and Drug Induced Liver Injury - etiology | Pituitary Diseases - chemically induced | Pituitary Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Drug Eruptions - etiology | Neoplasms - drug therapy | Cyclosporine - therapeutic use | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Melanoma - drug therapy | Chemical and Drug Induced Liver Injury - drug therapy | Diarrhea - drug therapy | CTLA-4 Antigen - antagonists & inhibitors | Kidney Neoplasms - drug therapy | Thyroiditis - drug therapy | Thyroiditis - chemically induced | Index Medicus
Journal Article